The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of intratumoral administration of HF10 in patients with refractory superficial cancer: Immune correlates of virus injection.
Neil Gildener-Leapman
Research Funding - Theradex
Robert L. Ferris
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Amgen; Bristol-Myers Squibb; Takara Bio; Theradex; VentiRx
James Ohr
Honoraria - Bayer/Onyx; Bristol-Myers Squibb; Genentech
Athanassios Argiris
No relevant relationships to disclose
John J. Nemunaitis
No relevant relationships to disclose
Neil N. Senzer
No relevant relationships to disclose
Cindi Bedell
No relevant relationships to disclose
Neil D. Gross
Research Funding - Takara Bio; Theradex
John T. Vetto
Honoraria - Merck
Maki Tanaka
Employment or Leadership Position - Takara Bio
Yukihiro Nishiyama
Consultant or Advisory Role - Takara Bio
Richard S. Ungerleider
Consultant or Advisory Role - Takara Bio